Context Therapeutics Inc. (CNTX)
(Delayed Data from NSDQ)
$1.86 USD
-0.10 (-5.10%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $1.86 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.86 USD
-0.10 (-5.10%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $1.86 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth D Momentum D VGM
Zacks News
Are Medical Stocks Lagging Context Therapeutics Inc. (CNTX) This Year?
by Zacks Equity Research
Here is how Context Therapeutics Inc. (CNTX) and Collegium Pharmaceutical (COLL) have performed compared to their sector so far this year.
Are Medical Stocks Lagging Context Therapeutics Inc. (CNTX) This Year?
by Zacks Equity Research
Here is how Context Therapeutics Inc. (CNTX) and Co-Diagnostics, Inc. (CODX) have performed compared to their sector so far this year.
Is CareCloud (CCLD) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how CareCloud, Inc. (CCLD) and Context Therapeutics Inc. (CNTX) have performed compared to their sector so far this year.
Are You Looking for a Top Momentum Pick? Why Context Therapeutics Inc. (CNTX) is a Great Choice
by Zacks Equity Research
Does Context Therapeutics Inc. (CNTX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Context Therapeutics Inc. (CNTX) Upgraded to Buy: Here's Why
by Zacks Equity Research
Context Therapeutics Inc. (CNTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Nasdaq ETF's First Six-week Rally Since Jan 2020: Stock Winners
by Sanghamitra Saha
Nasdaq ETF marked first six-week rally since Jan 2020. These stocks gained more than 100% during this time frame.